Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Teriflunomide has been associated with an increased risk of hypertension. Real-world studies including adequate control groups are lacking. We hypothesized that patients with multiple sclerosis (MS) treated with teriflunomide would be at higher risk of developing hypertension than those treated with dimethyl fumarate.
Methods: We conducted a cohort study linking the Danish Multiple Sclerosis Registry with national health registries during a 10-year period. Teriflunomide ( = 2656) and dimethyl fumarate ( = 2237) exposure was defined by the first treatment record lasting ⩾ 3 months, at which time follow-up started. We included 4893 adult patients without hypertension at baseline. Hypertension was defined as an International Classification of Diseases 10th Revision code for hypertension and by dispensed prescription drugs identified by the respective Anatomical Therapeutic Chemical codes. We used multivariable-adjusted Cox regression.
Results: We found 40.6 (teriflunomide) and 13.1 (dimethyl fumarate) hypertension events per 1000 person-years. Compared to dimethyl fumarate-treated patients, patients treated with teriflunomide had a higher risk of developing hypertension (adjusted hazard ratio = 2.80; 95% confidence interval = 2.19-3.56). The number needed to harm was 16 and 9 at 3 and 5 years of follow-up, respectively.
Conclusion: We found an increased risk of hypertension in adult patients with MS treated with teriflunomide.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/13524585241299715 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Teriflunomide Inhibits Human FOXP3 Regulatory T Cell Function by Interference With Mitochondrial Respiration.
Eur J Immunol
July 2025
Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research (IRC), Hasselt University, Diepenbeek, Belgium.
Regulatory FOXP3 T cells (Tregs) have been characterized with unique metabolic demands, preferentially relying on fatty acid β-oxidation (FAO) and oxidative phosphorylation (OXPHOS). Several studies have indicated that Treg mitochondrial fitness is crucial for maintaining their stability and suppressive activity with an emphasis on complex-III of the electron transport chain (ETC). Dysfunctional Tregs isolated from patients with autoimmunity like multiple sclerosis (MS) show diminished mitochondrial respiration and the induction of a T helper (Th)1-like phenotype, characterized by increased production of interferon (IFN)-γ.
View Article and Find Full Text PDFIncidence of peripheral neuropathy in patients treated with teriflunomide: A case series.
Med Clin (Barc)
August 2025
Grupo de Investigación en Neurociencias, Instituto de Investigación Sanitaria Aragón, Zaragoza, España; Servicio de Neurología, Hospital Royo Villanova, Zaragoza, España.
Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
J Neurol
August 2025
Centre de Ressources Biologiques Lorrain (CRBL), Centre Hospitalier Régional Universitaire de Nancy, Nancy, Grand Est, France.
Background: Platform therapies, such as dimethylfumarate, teriflunomide, and interferons beta, are insufficient to control relapsing-remitting multiple sclerosis in many patients. Having biomarkers available to stratify patients as good or poor responders before starting treatment would represent a considerable advance.
Methods: We tested serum and cerebrospinal fluid (CSF) levels of chitinase 3-like 1 (c and s-CHI3L1), soluble trigger receptor expressed on myeloid cells (sTREM2) and neuronal pentraxin 2 (NPTX2), and CSF levels of neurofilament light chains and of interleukin-6 (c-IL6) collected before treatment start in 70 patients in Eastern France.
Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score.
Mult Scler Relat Disord
August 2025
Department of Neurology, Medical University of Innsbruck, Austria. Electronic address:
Objective: To investigate whether the VIAADISC score predicts disease reactivation in relapsing multiple sclerosis (RMS) after de-escalation/discontinuation of disease-modifying-therapy (DMT) METHODS: We included RMS patients who i) received any DMT other than interferon-beta or glatiramer-acetate ≥12 months, ii) de-escalated/discontinued DMT, iii) had MRI before de-escalation/discontinuation, and iv) had ≥12 months of follow-up. VIAADISC score (0-6; age <45/45-54/≥55 = 2/1/0 points, MRI activity = 2 points, duration without clinical disease activity <4/4-8/>8 years = 2/1/0 points) was calculated. The primary endpoint was disease reactivation (relapse and/or disability progression).
View Article and Find Full Text PDFNeurologic Medication Costs in a Direct-to-Consumer Pharmacy vs Commercial Insurance Plans.
JAMA Netw Open
August 2025
Department of Neurology, Division of Health Services Research, Wexner Medical Center, The Ohio State University, Columbus.
Importance: Given increasing costs of neurologic medications, there is a need to explore alternative options to minimize medication spending.
Objective: To compare 2024 neurologic medication costs from commercial insurance plans with those available in the Mark Cuban Cost Plus Drug Company, a direct-to-consumer pharmacy.
Design, Setting, And Participants: This cross-sectional study compared medication costs through a direct-to-consumer pharmacy with model-estimated 2024 costs from commercial and Medicare supplemental databases.